Condition 1: Premenstrual syndrome. Condition 2: Dysmenorrhea. Premenstrual tension syndrome Primary dysmenorrhea
Conditions
Interventions
Intervention 1: Intervention group: The participants (31 people) will receive curcumin oral supplement in the form of gelatin capsules with a dosage of 500 mg with the trade name (Curcuma longa extrac
NOW®). Curcumin supplement contains a combination of curcumin and phosphatidylcholine. The time to take the supplement is once a day and after a meal. The duration of taking the supplement will be 10
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 25 Years
Inclusion criteria
Inclusion criteria: Regular menstruation (21-35 days) Having primary dysmenorrhea and premenstrual syndrome (with VAS score = 4 and PSST score = 20) Age 18-25 years Not allergic to turmeric Not taking any medicine to treat the symptoms of premenstrual syndrome at the same time as the research
Exclusion criteria
Exclusion criteria: Abuse of tobacco and alcohol Use of other herbal medicines The occurrence of a stressful event (such as the death of a first-degree family member and the diagnosis of an incurable disease for a family member during the last three months) Having any acute or chronic disease (such as epilepsy, cardiovascular, digestive, liver, blood, endocrine) History of any gynecological disease, such as abnormal pelvic anatomy, lack of ovulation, or abnormal pattern of uterine bleeding. Surgery in the last three months Taking antidepressants (such as serotonin and noradrenaline reuptake inhibitors, antihistamines, barbiturates, narcotics, diazepam, amphetamines, and cocaine) Taking anticoagulants such as heparin, aspirin, clopidogrel, dipyridamole, warfarin, enoxaparin and ticlopidine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Premenstrual syndrome. Timepoint: The first assessment before entering the study and the second assessment in one month after the intervention and the third assessment in 2 months after the intervention. Method of measurement: Premenstrual symptoms screening tool (PSST).;Dysmenorrhea. Timepoint: The first assessment before entering the study and the second assessment in one month after the intervention and the third assessment in 2 months after the intervention. Method of measurement: Visual analogue scale (VAS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSepideh Mashayekh Amiri
Tabriz University of Medical Sciences
Outcome results
None listed